New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
Dupixent peak sales ambition raised to more than €13 billion
Veritaz has over 40 brands marketed across the acute and critical care therapeutic segments
Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment
As part of this partnership, Huma and AstraZeneca will launch Software as a Medical Device (SaMD) companion apps targeted at several therapeutic areas and will partner to help accelerate the adoption of decentralized clinical trials
The investment will accelerate the overall Sarclisa development program
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers
As the world celebrates World Glaucoma Week (March 7-13th), Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals, an authority on eye diseases spoke to Thomas C Thottathil, Editor, indianpharmapost.com, on the seriousness of Glaucoma
Subscribe To Our Newsletter & Stay Updated
